Edward Lain, MD
Dermatology · Austin, TXNPI 1124079306
Payments from drug & device makers
Across 3,783 payments — averaging $3169.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4M
- Novartis$1.4M
- Eli Lilly$614K
- Incyte Corporation$465K
- Bausch Health US, LLC$429K
- Biofrontera Bioscience GmbH$422K
- plus $4.6M from 49 others
Across 93 payments — averaging $2204.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nielsen Biosciences, Inc.$91K
- Eli Lilly$43K
- Bausch Health US, LLC$29K
- AbbVie$21K
- Ichnos Glenmark Innovation Inc$18K
- Glenmark Pharmaceuticals Inc., USA$3K
What the payments were for
- Consulting fees$636,00125%
- Speaking & faculty fees$1,593,22263%
- Grants$82,5003%
- Travel & lodging$178,0157%
- Food & beverage$52,6292%
- Education$5,2120%
- Gifts$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,989,922 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $109,544 |
| Tacrolimus | 51 | $5,149 |
| Clobetasol Propionate | 62 | $2,679 |
| Fluorouracil | 37 | $2,047 |
| Ofloxacin | 11 | $1,826 |
| Ketoconazole | 147 | $1,801 |
| Metronidazole | 14 | $914 |
| Doxycycline Hyclate | 36 | $695 |
| Triamcinolone Acetonide | 56 | $642 |
| Minocycline Hcl | 22 | $485 |
| Minoxidil | 43 | $466 |
| ValacyclovirValacyclovir Hcl | 22 | $463 |
| Hydrocortisone | 61 | $334 |
| Spironolactone | 13 | $324 |
| Mupirocin | 38 | $251 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Austin
- Janet DuboisAustin$3.5M
- Daniel CarrascoAustin$1.4M
- Dale SchaeferAustin$1M
- Heidi PratherAustin$543K
- Ali ShahbazAustin$413K
- David BushoreAustin$385K
- Blakely RichardsonAustin$279K
- Stephen TyringWebster$14.1M
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.